REVIEW PAPER
Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology, and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland
1
Cervical Cancer Prevention Clinic, Central Coordinating Centre for Cervical Cancer Screening Programme, Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2
Obstetrics and Gynaecology Ward, District Specialist Hospital, Siedlce, Poland
3
Department of Endocrine Gynaecology, Collegium Medicum of the Jagiellonian University, Cracow, Poland; President of the Polish Society for Colposcopy and Cervical Pathophysiology, Vice President of the Polish Society of Gynaecologists and Obstetricians, Chairman of the Cervical Pathology, Colposcopy and Cytology Section of the Polish Society of Gynaecologists and Obstetricians, Member of the Board of the Polish Society of Oncological Gynaecology (PTGO), and Chairman of the Section for the prevention and treatment of cervical cancer at PTGO
4
Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; Polish Vaccinology Society
5
Department of Oncological Gynaecology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; National Consultant in Oncological Gynaecology
6
Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland
7
Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland; National Consultant in the field of Paediatrics, Polish Paediatric Society
8
Medical University in Lublin, Lublin, Poland; Polish Society of Oncological Gynaecology
9
Chair and Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; National Consultant in Family Medicine
10
Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland; Polish Society of Family Medicine
11
School of Public Health, Medical Centre of Postgraduate Education, Warsaw, Poland; National Consultant in Public Health
12
Chair and Department of Obstetrics, Women’s Diseases and Oncological Gynaecology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland; President of the Polish Society of Oncological Gynaecology
13
First Department of Gynaecology and Obstetrics, Medical University of Lodz, Lodz, Poland; President of the Polish Society of Gynaecologists and Obstetricians
14
Department of Gynaecological Oncology, Pomeranian Hospitals, Gdynia, Poland; Vice President of the Polish Society for Colposcopy and Cervical Pathophysiology
15
Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland
16
Observation and Infectious Diseases Department of the Specialist Mother and Child Healthcare Group in Poznan, Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznan, Poland; Polish Society of Vaccinology
Submission date: 2022-05-19
Acceptance date: 2022-05-28
Publication date: 2022-10-18
Pediatr Pol 2022;97(3):167-175
KEYWORDS
TOPICS
ABSTRACT
Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, and penile cancers, some head and neck cancers, and genital warts (condylomas). The fraction HPV-related cancers ranges from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out of pocket or in free- of-charge, local-governmental prevention programmes, but the vaccination coverage of the target population does not exceed 10%. In November 2021, one of the vaccines became available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teenage population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes is almost 100%, provided that full post-vaccination immunity is obtained before contact with the virus. Girls aged 11–13 years are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Programme (PIP) for all adolescents should be pursued. Persons over the age of 13 years may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.
REFERENCES (57)
3.
de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017; 141: 664-670.
4.
de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
5.
Nowakowski A, de Souza SC, Jach R, et al. HPV-type distribution and reproducibility of histological diagnosis in cervical neoplasia in Poland. Pathol Oncol Res 2015; 21: 703-711.
7.
World Health Organization. Weekly Epidemiological Record 2017; 92: 241-268. https://apps.who.int/iris/hand....
8.
Stanley M. HPV vaccines: alternative dosage schedules. Expert Rev Vaccines 2019; 18: 1309-1316.
9.
Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394: 497-509.
10.
Gidengil C, Goetz MB, Newberry S, et al. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 2021; 39: 3696-3716.
11.
Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine 2017; 35: 1729-1732.
12.
Hviid A, Thorsen NM, Valentiner-Branth P, et al. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. BMJ 2020; 370: m2930.
13.
Barboi A, Gibbons CH, Axelrod F, et al. Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clin Auton Res 2020; 30: 13-18.
14.
Gøtzsche PC, Jørgensen KJ. EMA’s mishandling of an investigation into suspected serious neurological harms of HPV vaccines. BMJ Evid Based Med 2022; 27: 7-10.
15.
Tatang C, Arredondo Bisonó T, Bergamasco A, et al. Human papillomavirus vaccination and premature ovarian failure: a disproportionality analysis using the vaccine adverse event reporting system. Drugs Real World Outcomes 2022; 9: 79-90.
16.
Bonaldo G, Vaccheri A, D’Annibali O, et al. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. Br J Clin Pharmacol 2019; 85: 634-643.
17.
Vichnin M, Bonanni P, Klein NP, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34: 983-991.
18.
Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711-723.
19.
Goss MA, Lievano F, Buchanan KM, et al. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015; 33: 3422-3428.
20.
Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med 2017; 376: 1223-1233.
21.
Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10-to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014; 33: 1255-1261.
22.
Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2: 868-878.
23.
Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial [published correction appears in Lancet Oncol 2012; 13: e1]. Lancet Oncol 2012; 13: 89-99.
24.
Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014; 32: 5087-5097.
25.
Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males [published correction appears in N Engl J Med 2011; 364: 1481]. N Engl J Med 2011; 364: 401-411.
26.
Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res 2020; 10: 100203.
27.
Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 2020; 23: 100401.
28.
Lehtinen M, Apter D, Eriksson T, et al. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial. Int J Cancer 2020; 147: 170-174.
29.
Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1: e8-e17.
30.
Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; 398: 2084-2092.
31.
Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383: 1340-1348.
32.
Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst 2021; 113: 1329-1335.
33.
Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Human papillomavirus vaccines effectiveness to prevent genital warts: a population-based study using health system integrated databases, 2009-2017. Vaccine 2022; 40: 316-324.
34.
Yuill S, Egger S, Smith M, et al. Has human papillomavirus (HPV) vaccination prevented adverse pregnancy outcomes? Population- level analysis after 8 years of a national HPV vaccination program in Australia. J Infect Dis 2020; 222: 499-508.
35.
Dehlendorff C, Baandrup L, Kjaer SK. Real-world effectiveness of human papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers. J Natl Cancer Inst 2021; 113: 869-874.
36.
Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of Prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol 2018; 36: 262-267.
37.
Denny LA, Franceschi S, de Sanjosé S, et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30 Suppl 5: F168-F174.
38.
Tanweer MS, Aljurf M, Savani BN, et al. Lower genital tract precancer and cancer in hematopoietic cell transplant survivors and the role of HPV: a systematic review and future perspectives. Clin Hematol Int 2019; 1: 142-153.
39.
Gómez de la Rosa AG, Quesada López-Fe A, Vilar Chesa M, et al. Efficacy of human papillomavirus vaccination 4 years after conization for high-grade cervical neoplasia. J Low Genit Tract Dis 2021; 25: 287-290.
40.
Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines (Basel) 2021; 9: 410.
41.
Sand FL, Kjaer SK, Frederiksen K, et al. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer 2020; 147: 641-647.
42.
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva; 2020.
43.
European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. Stockholm; 2020.
44.
Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68: 698-702.
45.
Uchwała nr 10 Rady Ministrów z dnia 4 lutego 2020 r. w sprawie przyjęcia programu wieloletniego pn. Narodowa Strategia Onkologiczna na lata 2020-2030, Dz.U. 2019 poz. 969 [In Polish].
46.
Rekomendacja nr 128/2021 z dnia 25 listopada 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie oceny leku Gardasil, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 6, 11, 16, 18] we wskazaniu: zapobieganie wystąpienia u osób w wieku od 9 lat: zmian przednowotworowych narządów płciowych (szyjki macicy, sromu i pochwy), zmian przednowotworowych odbytu, raka szyjki macicy oraz raka odbytu, związanych przyczynowo z zakażeniem pewnymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV); brodawek narządów płciowych (kłykcin kończystych) związanych przyczynowo z zakażeniem określonymi typami wirusa brodawczaka ludzkiego [In Polish].
47.
Rekomendacja nr 54/2021 z dnia 18 maja 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie objęcia refundacją leku Cervarix, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 16 i 18] we wskazaniu: profilaktyka zmian przednowotworowych narządów płciowych i odbytu (szyjki macicy, sromu, pochwy i odbytu) oraz raka szyjki macicy i raka odbytu związanych przyczynowo z określonymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV) u osób od ukończenia 9. roku życia [In Polish].
48.
Nowakowski A, Arbyn M, Turkot MH, et al. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev 2020; 29: 157-164.
49.
Bidziński M, Debski R, Kedzia W, et al. Stanowisko zespołu ekspertów Polskiego Towarzystwa Ginekologicznego na temat profilaktyki raka gruczołowego szyjki macicy. Ginekol Pol 2008; 79: 710-714.
50.
Chybicka A, Jackowska T, Dobrzańska A, et al. Zalecenia grupy ekspertów dotyczące pierwotnej profilaktyki raka szyjki macicy u dziewcząt i młodych kobiet. Pediatr Pol 2010; 85: 360-370.
51.
Agencja Oceny Technologii Medycznych i Taryfikacji, Wydział Oceny Technologii Medycznych. Profilaktyka zakażeń wirusem brodawczaka ludzkiego (HPV) w ramach programów polityki zdrowotnej Warszawa. Raport w sprawie zalecanych technologii medycznych, działań przeprowadzanych w ramach programów polityki zdrowotnej oraz warunków realizacji tych programów polityki zdrowotnej – materiały dla Rady Przejrzystości AOTMiT. Warszawa, 2019 [In Polish]; https://bipold.aotm.gov.pl/ass... (Accessed: 20.10.2021).
52.
Wydział Zdrowia i Spraw Społecznych Urzędu Miejskiego Wrocławia. Wrocławski program profilaktyki zakażeń wirusem brodawczaka ludzkiego [in Polish]; https://hpv.um.wroc.pl/?p=561 (Accessed: 20.10.2021).
53.
Ludwikowska KM, Szenborn L, Krzyżanowska I, et al. Potrzeba, bezpieczeństwo oraz realizacja szczepień przeciwko HPV – perspektywa wrocławska. Klin Pediatr 2018; 26: 26-30 [In Polish].
54.
Ludwikowska KM, Biela M, Szenborn L. HPV vaccine acceptance and hesitancy – lessons learned during 8 years of regional HPV prophylaxis program in Wroclaw, Poland. Eur J Cancer Prev 2020; 29: 346-349.
55.
Nguyen-Huu NH, Thilly N, Derrough T, et al. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine 2020; 38: 1315-1331.
56.
Brown B, Gabra MI, Pellman H. Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice. Papillomavirus Res 2017; 3: 42-45.
57.
Facciolà A, Visalli G, Orlando A, et al. Vaccine hesitancy: an overview on parents’ opinions about vaccination and possible reasons of vaccine refusal. J Public Health Res 2019; 8: 1436.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
